<DOC>
	<DOCNO>NCT01642004</DOCNO>
	<brief_summary>The purpose study compare overall survival BMS-936558 compare Docetaxel subject squamous cell non-small cell lung cancer ( NSCLC ) , failure prior platinum-based chemotherapy .</brief_summary>
	<brief_title>Study BMS-936558 ( Nivolumab ) Compared Docetaxel Previously Treated Advanced Metastatic Squamous Cell Non-small Cell Lung Cancer ( NSCLC ) ( CheckMate 017 )</brief_title>
	<detailed_description />
	<mesh_term>Lung Neoplasms</mesh_term>
	<mesh_term>Carcinoma , Non-Small-Cell Lung</mesh_term>
	<mesh_term>Docetaxel</mesh_term>
	<mesh_term>Nivolumab</mesh_term>
	<mesh_term>Antibodies , Monoclonal</mesh_term>
	<criteria>For information regard BMS clinical trial participation , please visit www.BMSStudyConnect.com Men woman ≥18 year age Subjects histologically cytologicallydocumented squamous cell NSCLC present Stage IIIB/IV disease recurrent progressive disease follow multimodal therapy ( radiation therapy , surgical resection definitive chemoradiation therapy locally advanced disease ) Disease recurrence progression during/after one prior platinum doubletbased chemotherapy regimen advance metastatic disease Measurable disease compute tomography ( CT ) /Magnetic resonance imaging ( MRI ) per Response Evaluation Criteria Solid Tumors ( RECIST ) 1.1 criterion Eastern Cooperative Oncology Group ( ECOG ) performance status ≤1 A formalin fix , paraffinembedded ( FFPE ) tumor tissue block unstained slide tumor sample ( archival recent ) must available biomarker evaluation . Specimens must receive central lab prior randomization . Biopsy excisional , incisional core needle . Fine needle aspiration insufficient Subjects untreated central nervous system ( CNS ) metastases exclude . Subjects eligible CNS metastasis treat subject neurologically return baseline least 2 week prior enrollment . In addition , subject must either corticosteroid , stable decrease dose ≤10 mg daily prednisone ( equivalent ) Subjects carcinomatous meningitis Subjects active , know suspected autoimmune disease . Subjects type I diabetes mellitus , hypothyroidism require hormone replacement , skin disorder ( vitiligo , psoriasis , alopecia ) require systemic treatment , condition expect recur absence external trigger permit enroll Subjects condition require systemic treatment either corticosteroid immunosuppressive medication within 14 day randomization Prior therapy antiProgrammed death1 ( PD1 ) , antiProgrammed cell death ligand 1 ( PDL1 ) , antiProgrammed cell death ligand 2 ( PDL2 ) , antiCD137 , antiCytotoxic T lymphocyteassociated antigen 4 ( CTLA4 ) antibody ( include ipilimumab antibody drug specifically target Tcell costimulation checkpoint pathway ) Prior treatment first line study CA184104 first line NSCLC study Prior treatment Docetaxel Subjects interstitial lung disease symptomatic may interfere detection management suspect drugrelated pulmonary toxicity Treatment investigational agent within 14 day first administration study treatment</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>December 2016</verification_date>
</DOC>